AlphaRx Inc.'s Newly Appointed President of China Operations Unveils Strategic Corporate Initiatives

HONG KONG--(Marketwire - December 21, 2009) - AlphaRx Inc.'s (OTCBB: ALRX) recently appointed President of China Operations, Ruby Hui, today announced new corporate initiatives and the company's strategic growth plan for China.

"When I was appointed as the President of AlphaRx China Operations a week ago, I promised that I would play a major part in AlphaRx's future and drive this company to new heights, and I am pleased to report that a strategic growth plan is now in place to fulfill that goal. AlphaRx is well positioned to leverage the momentum that has been building in the greater China region and is ready and able to play a major role in the fast growing China pharmaceutical market," Ms. Hui said.

"China's drug market is expected to expand at about 22% annually over the next five years. With an enormous and aging population, rapid urbanization and adoption of Western lifestyles that give rise to hypertension, obesity and other diseases, China is poised to become the world's third largest pharmaceutical market by 2013, up from its current number five position," she continued.

The company has assembled a portfolio of short and long-term drug candidates specifically to address the China market and these drugs should fuel sustainable revenue growth over the coming years. The company's product candidates are unique, protected by patents or patents pending and include the following:

Product Name            Dosage Form         Indication
                     ================== ==================
CHX Rinse                        Liquid        Gum Disease
                     ================== ==================
Indaflex                  Topical Cream               Pain
                     ================== ==================
Dicloflex                 Topical Cream               Pain
                     ================== ==================
ARX606T                   Topical Cream    Wound Treatment
                     ================== ==================
ARX2038                       Tablet ER       Anti-anxiety
                     ================== ==================
ARX2038                       Tablet ER   Lipid Management
                     ================== ==================
ARX1088                       Tablet ER          Hepatitis
                     ================== ==================
Zysolin              Inhalation Aerosol          Pneumonia
                     ================== ==================
Vansolin             Inhalation Aerosol          Pneumonia
                     ================== ==================
GAI-122                      Injectible             Stroke
                     ================== ==================

The "me-better" AlphaRx product strategy differentiates the company from generic market players and that oversubscribed "me-too" market. The company's well established business model of reformulating, repositioning and improving the efficacy of existing drugs is consistent with the Chinese government's own cost containment strategies and the company anticipates government support in the different stages of ongoing product development. In addition, it is planned to list AlphaRx's China Operations on a major stock exchange in the near future, to increase shareholder value. In short, the company is implementing a strategy of accelerated and sustainable future growth, with the goal of becoming the leading drug developer in the Chinese pharmaceutical market.

FORWARD-LOOKING STATEMENTS:

This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the Company.